A PYMNTS Company

AstraZeneca’s $39B Alexion Buy Clears FTC Review

By  |  April 18, 2021

AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company stated.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Cambridge, UK, pharmaceutical and biotechnology company said the US clearance follows competition clearances in Canada, Brazil, Russia, and other countries globally.

    “Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan,” the company added.

    The deal is valued at US$39 billion. AstraZeneca expects to close the acquisition in the third quarter. 

    AstraZeneca in December agreed to pay US$175 a share for the Boston  pharmaceutical company, which is known for its focus on rare and ultra-rare disease. Alexion holders will own around 15% of AstraZeneca’s shares outstanding when the deal closes.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.